Application of molecular markers in the diagnostics of thyroid focal lesions – current state of knowledge
Journal Title: OncoReview - Year 2012, Vol 2, Issue 2
Abstract
Thyroid nodular disease is a common disorder and affects about 20% of adult polish population. Due to the fact that methods currently applied in routine assessment of these changes often do not provide accurate diagnosis, the research are ongoing to identify novel markers of malignancy, including molecular ones. Thus far not a single marker was found, which characterises with satisfying sensitivity and specificity in the preoperative differentiation of benign and malignant thyroid lesions. None of the developed potential markers was included to the routine diagnostic procedures or guidelines, either. However, intensive research aiming to search for novel molecular markers, optimization of methods of detection and evaluation of their true clinical utility bring more and more promising results. Analysis of not a single studied marker cannot serve as independent diagnostic method. However, examination of a group of several markers, together with ultrasound examination and classic cytological examination, may contribute to the increase in sensitivity and specificity in detection of malignant lesions and thus, make further therapeutic decisions in a patient with thyroid nodular disease easier.
Authors and Affiliations
Marek Ruchała, Kosma Woliński, Maciej Fularz, Ewelina Szczepanek-Parulska
Keywords
Related Articles
- EP ID EP53150
- DOI -
- Views 220
- Downloads 0
Early diagnostics and prevention of anthracycline-induced cardiomyopathy – the role of cardiologist
Anticancer antibiotics, anthracyclines, may cause severe left ventricle systolic dysfunction that is associated with poor clinical prognosis. In this review, we discuss the mechanisms and risk factors of anthracycline-in...
Wybrane aspekty stosowania inhibitorów kinaz tyrozynowych w terapii chorych na nowotwory podścieliskowe przewodu pokarmowego
Nowotwory podścieliskowe przewodu pokarmowego (GIST, gastrointestinal stromal tumor) są najczęstszymi nowotworami złośliwymi pochodzenia mezenchymalnego przewodu pokarmowego. Najczęściej umiejscawiają się w żołądku i jel...
Late relapse of chronic myeloid leukemia after allogeneic stem cell tranplan
Chronic myeloid leukemia now is a disease which in the most cases is well manageable with tyrosine kinase inhibitors treatment. Still however the only potentially curable therapeutic approach is for chronic myeloid leuke...
Targeted therapies for chronic myeloid leukemia and cardiovascular system
Morbidity of chronic myeloid leukemia is recorded in elderly population, in patients with coexisting significant risk factors for atherosclerosis and heart diseases. Molecularly targeted therapy, imatinib, dasatinib and...
Management strategy of patients with chronic myeloid leukemia in chronic phase who failed to response to imatinib – Kraków Haematology Clinic experience
Introduction: Tyrosine kinase inhibitors eliminate chronic myeloid leukemia cells in a targeted way. The resistance to this therapy was the cause of development of treatment recommendations and drugs of second and subseq...